Drug intelligence / Profile preview

Enterococcus faecium M-74

Development stage: Unknown
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Enterococcus faecium M-74 is a **probiotic bacterial strain** that has been studied for its cholesterol-lowering effects and gastrointestinal health benefits. The strain demonstrates the ability to reduce serum cholesterol levels through production of a hydrolase enzyme that catalyzes bile acid deconjugation and assists in cholesterol integration into the bacterial cell wall. In clinical studies, administration of E. faecium M-74 enriched with selenium resulted in a **12% reduction in total cholesterol** and significant decreases in LDL cholesterol after 56 weeks of daily use. The strain has been investigated for treating gastrointestinal complications in patients with myeloid leukemia. E. faecium M-74 is typically formulated with organically bound selenium (50 μg) at a dose of 2×10^9 colony-forming units per capsule for oral administration.

Other names: E. faecium M-74EF M-74

Beyond the preview

Go deeper on Enterococcus faecium M-74.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterococcus faecium M-74.

Explore the full profile